ALPS Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-7,535
| Closed | -$335K | – | 1204 |
|
|
2022
Q2 | $335K | Buy |
+7,535
| New | +$335K | ﹤0.01% | 717 |
|
|
2021
Q2 | – | Sell |
-23,570
| Closed | -$984K | – | 923 |
|
|
2021
Q1 | $984K | Sell |
23,570
-1,025
| -4% | -$42.8K | 0.01% | 400 |
|
|
2020
Q4 | $1.15M | Buy |
+24,595
| New | +$1.15M | 0.01% | 373 |
|
|
2020
Q1 | – | Sell |
-5,913
| Closed | -$355K | – | 952 |
|
|
2019
Q4 | $355K | Sell |
5,913
-258
| -4% | -$15.5K | ﹤0.01% | 711 |
|
|
2019
Q3 | $349K | Sell |
6,171
-1,779
| -22% | -$101K | ﹤0.01% | 758 |
|
|
2019
Q2 | $443K | Sell |
7,950
-420
| -5% | -$23.4K | ﹤0.01% | 574 |
|
|
2019
Q1 | $423K | Buy |
8,370
+1,612
| +24% | +$81.5K | ﹤0.01% | 592 |
|
|
2018
Q4 | $272K | Sell |
6,758
-336
| -5% | -$13.5K | ﹤0.01% | 822 |
|
|
2018
Q3 | $492K | Sell |
7,094
-1,104
| -13% | -$76.6K | ﹤0.01% | 644 |
|
|
2018
Q2 | $620K | Sell |
8,198
-384
| -4% | -$29K | ﹤0.01% | 475 |
|
|
2018
Q1 | $452K | Buy |
8,582
+1,288
| +18% | +$67.8K | ﹤0.01% | 708 |
|
|
2017
Q4 | $390K | Sell |
7,294
-500
| -6% | -$26.7K | ﹤0.01% | 685 |
|
|
2017
Q3 | $465K | Buy |
7,794
+1,809
| +30% | +$108K | ﹤0.01% | 642 |
|
|
2017
Q2 | $472K | Buy |
5,985
+16
| +0.3% | +$1.26K | ﹤0.01% | 564 |
|
|
2017
Q1 | $495K | Buy |
+5,969
| New | +$495K | ﹤0.01% | 436 |
|
|
2016
Q4 | – | Sell |
-19,933
| Closed | -$1.4M | – | 736 |
|
|
2016
Q3 | $1.4M | Sell |
19,933
-2,032
| -9% | -$142K | 0.01% | 206 |
|
|
2016
Q2 | $852K | Buy |
+21,965
| New | +$852K | 0.01% | 211 |
|